Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| EVO756 (MRGPRX2 Antagonist) | Moderate-To-Severe Atopic Dermatitis | Phase 2b | Sep 30, 2026 | Mgmt interest |
| EVO756 (MRGPRX2 Antagonist) | Migraine | Phase 2b | Dec 31, 2027 | — |
Upcoming milestones
Company profile
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Moderate-To-Severe Atopic Dermatitis
Migraine
Data readout